Product Pipeline

Combination Therapies Designed to Activate the Body’s Own T-cells to Fight Cancer

Our pipeline is focused on T-cell activation and co-stimulation as well as dual-acting immunotherapies that incorporate a T-cell activator and a T-cell co-stimulator into a single injection to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologic products.

Combination Therapies Indication Preclinical Phase 1 Phase 2 Phase 3 Market Comments

HS-110

(viagenpumatucel-L)

NSCLC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started
ImPACT® activation technology in combination with nivolumab and other checkpoint inhibitors TBA

HS-130

(viagenpumatucel-L)

NSCLC
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
ComPACT™ activation technology in combination with checkpoint inhibitors TBA
Co-Stimulators

PTX-35

(viagenpumatucel-L)

TBA
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Humanized monoclonal antibody, functional agonist of human TNFRSF25

HS-110 Phase 2 Clinical Trial

HS-110 is in Phase 2 study for the potential treatment of non-small cell lung cancer (NSCLC), in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®). Our therapeutic drug is designed to secrete a wide range of lung cancer-associated antigens bound to gp96 proteins while activating a broad, T-cell mediated immune response against cancer.

View Candidate